Breaking News
Subscribe Now 0
📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI. See top stocks
Close

Alzamend Neuro Inc (ALZN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Alzamend Neuro's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.5600 +0.0100    +0.65%
03:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.5600
0.0000
0.0000%
7:33:01 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 103,189
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.5001 - 1.5800
Alzamend Neuro 1.5600 +0.0100 +0.65%

Alzamend Neuro Inc Company Profile

 
Get an in-depth profile of Alzamend Neuro Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

6

Equity Type

ORD

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Contact Information

Address 3480 Peachtree Road NE Second Floor, Suite 103
Atlanta, 30326
United States
Phone 844 722 6333
Fax -

Top Executives

Name Age Since Title
Henry C.W. Nisser 52 2019 Executive VP, General Counsel & Director
Stephan Jackman 46 2018 CEO & Director
William B. Horne 55 2016 Chairman of the Board
Henry C. W. Nisser 55 2019 Executive VP, General Counsel & Director
Terri Hunter - 2022 Member of Scientific Advisory Board
Jeffrey Oram 56 2021 Independent Director
Andrew H. Woo 60 2021 Independent Director
Mark Garland Gustafson 64 2021 Independent Director
Eric M. McDade - - Member of Scientific Advisory Board
Lynne Fahey McGrath 68 2021 Independent Director
Thomas M. Wisniewski - 2019 Member of Scientific Advisory Board
Milton Charles Ault 54 2016 Founder & Vice Chairman
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALZN Comments

Write your thoughts about Alzamend Neuro Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email